As of 102018 Aducanumab amyloid antibody Biogen Albumin Immunoglobulin treats primary immunodeficiency G rifols Biologicals ALZTOP1 Mast cell stabilizer antiinflammatory AZTherapies ID: 736928
Download Presentation The PPT/PDF document "Therapeutic Agents in Phase III Clinical..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Therapeutic Agents in Phase III Clinical Trials for Alzheimer’s (Registration Trials)
ALZT-OP1: Mast cell stabilizer + anti-inflammatory
AZTherapiesANAVEX2-73: Muscarinic agonist and sigma receptor agonistAnavex Life SciencesBAN2401: antibody binding to large, soluble Aβ protofibrilsEisaiCAD-106: amyloid vaccine NovartisCNP520: BACE inhibitorNovartisCOR388: Peptide hydrolase inhibitorsCortexymeCrenezumab: amyloid antibodyHoffmann-La RocheElenbecestat (E2609): BACE inhibitorEisai, BiogenGantenerumab: amyloid antibodyHoffmann-La Roche
Levetiracetam: beta-amyloid production inhibitorAgeneBioMasitinib (Masivet): tyrosine kinase inhibitorAB ScienceMB2 (TRx0237, Methylene Blue): tau aggregation inhibitor TauRx Therapeutics LtdPimavanserin: selective inverse agonist of serotonin 5-HT2A receptorAcadia PharmaceuticalsSolanezumab: amyloid antibodyEli LillyTrigriluzole: Pro-drug of riluzole, a glutamate modulator agent Biohaven Pharmaceuticals
For related symptoms:AVP-786 (agitation): combination of Deuterated [d6]-Dextromethorphan Hydrobromide and Quinidine SulfateAvanir PharmaceuticalsBrexpiprazole (agitation): dopamine D2 receptor partial agonistOtsuka PharmaceuticalsPimavanserin (psychosis): selective inverse agonist of serotonin 5-HT2A receptor Acadia Pharmaceuticals
As of 04/2019Slide2
Therapeutic Agents in Phase III Clinical Trials for Alzheimer’s (Academic Trials)
Curcumin: nutritional supplement
University of FloridaErgothioneine: nutritional supplementNational University Hospital, SingaporeGantenerumab: amyloid antibodyWashington University School of Medicine, Hoffmann-La RocheGuanfacine: α2A receptor agonistImperial College LondonHuman neural stem cells: pluripotent cell lineSecond Affiliated Hospital of Soochow UniversityIcosapent Ethyl/ Omega-3 fatty acid: nutritionalVA Office of Research and Development; University of Southern California; University Hospital, ToulouseJNJ-54861911 (atabecestat): BACE inhibitorWashington UniversityLosartan, Amlodipine & Atorvastatin combination therapy: blood pressure reducers
University of Texas Southwestern Medical CenterOctohydroaminoacridine Succinate: acetylcholinesterase inhibitorShanghai Mental Health CenterVitamin D3: nutritional supplementUniversity Hospital, ToursFor related symptoms:Escitalopram (agitation): selective serotonin reuptake inhibitor (SSRI)Johns Hopkins School of Public Health Center for Clinical TrialsMethylphenidate: norepinephrine–dopamine reuptake inhibitor (NDRI) (Apathy)Johns Hopkins Bloomberg School of Public HealthMirtazapine (agitation): atypical antidepressantUniversity of SussexNabilone/
Dronabinol (agitation): synthetic cannabinoidSunnybrook Health Sciences CentreZolpidem (sleep): Short-acting nonbenzodiazepineBrasilia University HospitalZoplicone (sleep): Nonhypnotic sleep aidBrasilia University HospitalAs of 04/2019